At least four MEK inhibitors, mirdametinib (PD0325901), trametinib (GSK1120212, Mekinist), binimetinib (ARRY‐438162, MEK162), and selumetinib (AZD6244), have progressed to clinical trials in NF1 patients and, at the time of writing, ClinicalTrials.gov lists 23 trials to evaluate these MEK inhibitors for various manifestations of NF1 (Table 1). Here, MAP2K7 is linked to neurofibromatosis type 1.